Novamind Inc. (CNSX:NM)(OTC PINK:NVMDF) wholly owned subsidiary Cedar Clinical Research (CCR) has been selected to partner with leading pharmaceutical company Merck & Co Inc. (MRK) in clinical trial focusing on new treatment-resistant depression drug developed by Merck.
The two companies will be carrying out phase II study to measure the efficiency and safety of a new drug for treatment-resistant depression (TRD), this is a mental health condition which affects about 30% of individuals who suffer from major depressive disorder.
The clinical trial is set to kick off this month, it has been named “A Phase 2a, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-1942 Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression.”
Novamind’s Chief Medical Officer and CCR’s Principal Investigator Dr. Reid Robison expressed how proud they were having been selected for the trial further adding CCR has a special expertise in conducting clinical trials and research studies in neuropsychiatry.
“We’re proud to partner with Merck and support its innovative neuroscience work to develop a potential new drug for treatment-resistant depression,” said Dr Robison.
